Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 1998, p. 3200-3208, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
In Vitro Inhibition of Hepadnavirus Polymerases by
the Triphosphates of BMS-200475 and Lobucavir
Maria
Seifer,
Robert K.
Hamatake,
Richard J.
Colonno, and
David N.
Standring*
Pharmaceutical Research Institute,
Bristol-Myers Squibb, Wallingford, Connecticut 06492
Received 3 February 1998/Returned for modification 1 May
1998/Accepted 15 September 1998
The guanosine analogs BMS-200475 and lobucavir have previously been
shown to effectively suppress propagation of the human hepatitis B
virus (HBV) and woodchuck hepatitis virus (WHV) in 2.2.15 liver cells
and in the woodchuck animal model system, respectively. This repression
was presumed to occur via inhibition of the viral polymerase (Pol) by
the triphosphate (TP) forms of BMS-200475 and lobucavir which are
both produced in mammalian cells. To determine the exact mode of
action, BMS-200475-TP and lobucavir-TP, along with several other
guanosine analog-TPs and lamivudine-TP were tested against the HBV,
WHV, and duck hepatitis B virus (DHBV) polymerases in vitro.
Estimates of the 50% inhibitory concentrations revealed that
BMS-200475-TP and lobucavir-TP inhibited HBV, WHV, and DHBV Pol
comparably and were superior to the other nucleoside-TPs tested. More
importantly, both analogs blocked the three distinct phases of
hepadnaviral replication: priming, reverse transcription, and
DNA-dependent DNA synthesis. These data suggest that the modest potency
of lobucavir in 2.2.15 cells may be the result of poor phosphorylation
in vivo. Kinetic studies revealed that BMS-200475-TP and lobucavir-TP
competitively inhibit HBV Pol and WHV Pol with respect to the
natural dGTP substrate and that both drugs appear to bind to Pol with
very high affinities. Endogenous sequencing reactions
conducted in replicative HBV nucleocapsids suggested that
BMS-200475-TP and lobucavir-TP are nonobligate chain terminators that
stall Pol at sites that are distinct yet characteristically two to
three residues downstream from dG incorporation sites.
*
Corresponding author. Present mailing address:
Schering-Plough Research Institute, 2015 Galloping Hill Rd.,
Kenilworth, NJ 07033-0539. Phone: (908) 740-7446. Fax: (908)
740-3918. E-mail: david.standring{at}spcorp.com.

Present address: Schering-Plough Research Institute, Kenilworth, NJ
07033-0539.

Present address: GlaxoWellcome, Research Triangle Park, NC
27709.
Antimicrobial Agents and Chemotherapy, December 1998, p. 3200-3208, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Michalak, T. I., Zhang, H., Churchill, N. D., Larsson, T., Johansson, N.-G., Oberg, B.
(2009). Profound Antiviral Effect of Oral Administration of MIV-210 on Chronic Hepadnaviral Infection in a Woodchuck Model of Hepatitis B. Antimicrob. Agents Chemother.
53: 3803-3814
[Abstract]
[Full Text]
-
Scarsi, K. K., Darin, K. M.
(2009). Chronic Hepatitis B Infection: Principles of Therapy. Journal of Pharmacy Practice
22: 359-387
[Abstract]
-
Tchesnokov, E. P., Obikhod, A., Schinazi, R. F., Gotte, M.
(2008). Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase. J. Biol. Chem.
283: 34218-34228
[Abstract]
[Full Text]
-
Lin, L., Hu, J.
(2008). Inhibition of Hepadnavirus Reverse Transcriptase-{varepsilon} RNA Interaction by Porphyrin Compounds. J. Virol.
82: 2305-2312
[Abstract]
[Full Text]
-
Domaoal, R. A., McMahon, M., Thio, C. L., Bailey, C. M., Tirado-Rives, J., Obikhod, A., Detorio, M., Rapp, K. L., Siliciano, R. F., Schinazi, R. F., Anderson, K. S.
(2008). Pre-steady-state Kinetic Studies Establish Entecavir 5'-Triphosphate as a Substrate for HIV-1 Reverse Transcriptase. J. Biol. Chem.
283: 5452-5459
[Abstract]
[Full Text]
-
Mazzucco, C. E., Hamatake, R. K., Colonno, R. J., Tenney, D. J.
(2008). Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition. Antimicrob. Agents Chemother.
52: 598-605
[Abstract]
[Full Text]
-
Langley, D. R., Walsh, A. W., Baldick, C. J., Eggers, B. J., Rose, R. E., Levine, S. M., Kapur, A. J., Colonno, R. J., Tenney, D. J.
(2007). Inhibition of Hepatitis B Virus Polymerase by Entecavir. J. Virol.
81: 3992-4001
[Abstract]
[Full Text]
-
Tenney, D. J., Rose, R. E., Baldick, C. J., Levine, S. M., Pokornowski, K. A., Walsh, A. W., Fang, J., Yu, C.-F., Zhang, S., Mazzucco, C. E., Eggers, B., Hsu, M., Plym, M. J., Poundstone, P., Yang, J., Colonno, R. J.
(2007). Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present. Antimicrob. Agents Chemother.
51: 902-911
[Abstract]
[Full Text]
-
Jacquard, A.-C., Brunelle, M.-N., Pichoud, C., Durantel, D., Carrouee-Durantel, S., Trepo, C., Zoulim, F.
(2006). In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2',3'-Dideoxy-3'-Fluoroguanosine. Antimicrob. Agents Chemother.
50: 955-961
[Abstract]
[Full Text]
-
Kim, J. W, Park, S. H, Louie, S. G
(2006). Telbivudine: A Novel Nucleoside Analog for Chronic Hepatitis B. The Annals of Pharmacotherapy
40: 472-478
[Abstract]
[Full Text]
-
Delaney, W. E. IV, Yang, H., Miller, M. D., Gibbs, C. S., Xiong, S.
(2004). Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro. Antimicrob. Agents Chemother.
48: 3702-3710
[Abstract]
[Full Text]
-
Tenney, D. J., Levine, S. M., Rose, R. E., Walsh, A. W., Weinheimer, S. P., Discotto, L., Plym, M., Pokornowski, K., Yu, C. F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S., Colonno, R. J.
(2004). Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine. Antimicrob. Agents Chemother.
48: 3498-3507
[Abstract]
[Full Text]
-
Cai, Z., Liang, T. J., Luo, G.
(2004). Effects of Mutations of the Initiation Nucleotides on Hepatitis C Virus RNA Replication in the Cell. J. Virol.
78: 3633-3643
[Abstract]
[Full Text]
-
Kamiya, N.
(2003). The mechanisms of action of antivirals against hepatitis B virus infection. J Antimicrob Chemother
51: 1085-1089
[Full Text]
-
Karayiannis, P.
(2003). Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother
51: 761-785
[Abstract]
[Full Text]
-
Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S., Colonno, R. J.
(2002). Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro. Antimicrob. Agents Chemother.
46: 2525-2532
[Abstract]
[Full Text]
-
Gaillard, R. K., Barnard, J., Lopez, V., Hodges, P., Bourne, E., Johnson, L., Allen, M. I., Condreay, P., Miller, W. H., Condreay, L. D.
(2002). Kinetic Analysis of Wild-Type and YMDD Mutant Hepatitis B Virus Polymerases and Effects of Deoxyribonucleotide Concentrations on Polymerase Activity. Antimicrob. Agents Chemother.
46: 1005-1013
[Abstract]
[Full Text]
-
Marion, P. L., Salazar, F. H., Winters, M. A., Colonno, R. J.
(2002). Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication. Antimicrob. Agents Chemother.
46: 82-88
[Abstract]
[Full Text]
-
Le Guerhier, F., Pichoud, C., Guerret, S., Chevallier, M., Jamard, C., Hantz, O., Li, X.-Y., Chen, S.-H., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F.
(2000). Characterization of the Antiviral Effect of 2',3'-Dideoxy-2', 3'-Didehydro-beta -L-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model. Antimicrob. Agents Chemother.
44: 111-122
[Abstract]
[Full Text]
-
Genovesi, E. V., Lamb, L., Medina, I., Taylor, D., Seifer, M., Innaimo, S., Colonno, R. J., Standring, D. N., Clark, J. M.
(1998). Efficacy of the Carbocyclic 2'-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection. Antimicrob. Agents Chemother.
42: 3209-3217
[Abstract]
[Full Text]